Skip to main content

Table 4 Correlations1 among PROs at baseline and week 12, and change from baseline to week 12

From: The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Measure Baseline Week 12 Change
  DLQI Total EQ-5D Index EQ-5D VAS DLQI Total EQ-5D Index EQ-5D VAS DLQI Total EQ-5D Index EQ-5D VAS
DLQI Total Score 1.00 -0.51 -0.35 1.00 -0.71 -0.58 1.00 -0.53 -0.46
SF-36          
   Physical Functioning -0.44 0.58 0.35 -0.41 0.61 0.49 -0.29 0.47 0.32
   Role-Physical -0.45 0.64 0.38 -0.57 0.67 0.50 -0.47 0.51 0.45
   Bodily Pain -0.55 0.73 0.45 -0.61 0.76 0.56 -0.66 0.64 0.53
   General Health -0.24** 0.39 0.47 -0.38 0.59 0.69 -0.33 0.46 0.46
   Vitality -0.31 0.43 0.48 -0.43 0.62 0.60 -0.46 0.37 0.48
   Social Functioning -0.69 0.52 0.46 -0.68 0.74 0.60 -0.68 0.50 0.56
   Role-Emotional -0.41 0.45 0.42 -0.56 0.67 0.53 -0.50 0.41 0.48
   Mental Health -0.44 0.46 0.50 -0.56 0.66 0.67 -0.52 0.49 0.56
   Physical Summary Score (PCS) -0.41 0.64 0.36 -0.46 0.65 0.52 -0.41 0.56 0.39
   Mental Summary Score (MCS) -0.45 0.39 0.49 -0.58 0.66 0.63 -0.59 0.42 0.57
EQ-5D          
Index Score -0.51 1.00 0.39 -0.71 1.00 0.63 -0.53 1.00 0.39
VAS-General Health -0.35 0.39 1.00 -0.58 0.63 1.00 -0.46 0.39 1.00
  1. 1All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, **p ≤ 0.01, ns = non-significant.